FRACTYL HEALTH, INC.

Press Releases Fractyl Health, Inc.

Equities

GUTS

US35168W1036

Real-time Estimate Cboe BZX Other stock markets 07:46:54 31/05/2024 pm IST			5-day change	1st Jan Change
6.665 ^USD	-0.82%		-10.79%	0.00%

20/05	Fractyl Health, Inc. Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva At Digestive Disease Week 2024	CI
13/05	Earnings Flash (GUTS) FRACTYL HEALTH Reports Q1 Revenue $33,000	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions	29/05	GL
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024	20/05	GL
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates	14/05	GL
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)	13/05	GL
Fractyl Health to Present at BofA Securities 2024 Health Care Conference	08/05	GL
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024	07/05	GL
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting	30/04	GL
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes	02/04	GL
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes	02/04	AQ
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	01/04	GL
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs	01/04	GL
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity	12/03	GL
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials	20/02	GL
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials	20/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer